A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma. Issue 1 (January 2022)

• Record Type: Journal Article
• Authors: Brambati, Maria; Giuffrè, Chiara; Marchese, Alessandro; Bandello, Francesco; Modorati, Giulio Maria; Miserocchi, Elisabetta
• Is Part Of: European journal of ophthalmology. Volume 32:Issue 1(2022)
• Page Start: NP109
• Page End: NP113
• Publication Date: 2022-01
• Subjects: Immunology -- choroidal/retinal inflammation -- UVEA -- panuveitis -- UVEITIS -- systemic drug retinal toxicity -- RETINA -- pharmacology; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; 617.7005
• DOI: 10.1177/1120672120962044
• Languages: English
• ISSNs: 1120-6721

Abstract

We report a case of ocular drug toxicity consistent with bilateral Vogt-Koyanagi-Harada (VKH) like disease in a patient with cutaneous melanoma treated with Dabrafenib/Trametinib therapy. A 53-year-old man with a history of metastatic cutaneous melanoma, treated with Dabrafenib/Trametinib, developed a severe acute panuveitis with granulomatous anterior uveitis and multiple serous retinal detachments. The ocular inflammatory reaction was classified as a bilateral Vogt-Koyanagi-Harada disease. Intraocular inflammation resolved after discontinuation of chemotherapeutic agents and aggressive topical and systemic corticosteroid therapy. The present case outlines the importance of recognizing VKH-like syndrome as a possible consequence of therapy with dabrafenib and trametinib.